2026-06-29T03:13:43Zhttps://docta.ucm.es/rest/oai/requestoai:docta.ucm.es:20.500.14352/130012025-01-20T17:14:47Zcom_20.500.14352_14col_20.500.14352_15
Docta Complutense
author
Gil Ordóñez, Ana
author
Martín-Fontecha Corrales, María Del Mar
author
Ortega Gutiérrez, Silvia
author
López Rodríguez, María Luz
2023-06-17T13:18:48Z
2023-06-17T13:18:48Z
2018-11
0006-2952
10.1016/j.bcp.2018.07.036
https://hdl.handle.net/20.500.14352/13001
https://doi.org/10.1016/j.bcp.2018.07.036
https://www.sciencedirect.com/science/article/pii/S0006295218303046
Monoacylglycerol lipase (MAGL) has been characterized as the main enzyme responsible for the inactivation of the most abundant brain endocannabinoid, 2-arachidonoylglycerol (2-AG). Besides this role, MAGL has progressively acquired a growing importance as an integrative metabolic hub that controls not only the in vivo levels of 2-AG but also of other monoacylglycerides and, indirectly, the levels of free fatty acids derived from their hydrolysis as well as other lipids with pro-inflammatory or pro-tumorigenic effects, coming from the further metabolism of fatty acids. All these functions have only started to be elucidated in the last years due to the progress made in the knowledge of the structure of MAGL and in the development of genetic and chemical tools. In this review we report the advances made in the field with a special focus on the last decade and how MAGL has become a promising therapeutic target for the treatment of several diseases that currently lack appropriate therapies.
eng
Monoacylglycerol lipase (MAGL) as a promising therapeutic target
journal article
URL
https://docta.ucm.es/bitstreams/2018e6e6-e1fb-4f9f-bfaa-08606ef09d47/download
File
MD5
02a61646494d7449d8ac32108ceb7da9
1418994
application/pdf
Mar Martin Fontecha1-s2.0-S0006295218303046-main.pdf
URL
https://docta.ucm.es/bitstreams/d08534d2-ba97-4ea1-94b4-72643bc2cedb/download
File
MD5
c02b5784b191d91778d932a6902f21ba
145485
text/plain
Mar Martin Fontecha1-s2.0-S0006295218303046-main.pdf.txt